Ginkgo Bioworks acquires biotech start-ups Altar and Circularis

摘要

The synthetic biology company Ginkgo Bioworks has announced the acquisition of biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Both companies are located in Oakland, California, USA. The news comes just months after Ginkgo's largest acquisition to date - when the company acquired Zymergen for US$300M this past summer. Founded in 2017, Altar has developed a proprietary adaptive evolution platform (based on their Genemat technology) which enables continuous cultivation of microorganisms under selective pressure controlled by algorithms. Ginkgo's acquisition will bring Altar's automated adaptive laboratory evolution (ALE) instruments to Ginkgo's Foundry in Boston.